Leprosy

被引:588
作者
Britton, WJ
Lockwood, DNJ
机构
[1] Univ Sydney, Centenary Inst Canc Med & Cell Biol, Sydney, NSW 2006, Australia
[2] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[3] London Sch Hyg & Trop Med, London WC1, England
[4] Hosp Trop Dis, London NW1 0PE, England
关键词
D O I
10.1016/S0140-6736(04)15952-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leprosy remains an important health problem worldwide. The disease is caused by a chronic granulomatous infection of the skin and peripheral nerves with Mycobacterium leprae. The clinical range from tuberculoid to lepromatous leprosy is a result of variation in the cellular immune response to the mycobacterium. The resulting impairment of nerve function causes the disabilities associated with leprosy. This review summarises recent advances in understanding of the biology of leprosy, clinical features of the disease, the current diagnostic criteria, and the new approaches to treatment of the infection and the immune-mediated complications. Supervised multi-drug therapy (MDT) for fixed durations is highly effective for all forms of the disease. The widespread implementation of MDT has been associated with a fall in the prevalence of the leprosy but as yet no reduction in the case-detection rate globally. Thus, leprosy control activities must be maintained for decades to Interrupt transmission of infection.
引用
收藏
页码:1209 / 1219
页数:11
相关论文
共 139 条
[21]  
Dasananjali K, 1997, INT J LEPROSY, V65, P28
[22]  
de Oliveira MLW, 1998, WHO TECH REP SER, V874, P1
[23]  
deJong R, 1997, J IMMUNOL, V159, P786
[24]   A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents [J].
Dockrell, HM ;
Brahmbhatt, S ;
Robertson, BD ;
Britton, S ;
Fruth, U ;
Gebre, N ;
Hunegnaw, M ;
Hussain, R ;
Manandhar, R ;
Murillo, L ;
Pessolani, MCV ;
Roche, P ;
Salgado, JL ;
Sampaio, E ;
Shahid, F ;
Thole, JER ;
Young, DB .
INFECTION AND IMMUNITY, 2000, 68 (10) :5846-5855
[25]  
Durrheim DN, 2002, LEPROSY REV, V73, P326
[26]  
Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6
[27]   Minocycline-induced hyperpigmentation in leprosy [J].
Fleming, CJ ;
Hunt, MJ ;
Salisbury, ELC ;
McCarthy, SW ;
Barnetson, RS .
BRITISH JOURNAL OF DERMATOLOGY, 1996, 134 (04) :784-787
[28]  
García VE, 1999, J IMMUNOL, V162, P6114
[29]  
Garcia VE, 1997, J IMMUNOL, V159, P1328
[30]  
Gebre S, 2000, LEPROSY REV, V71, P325